KOZARICH JOHN W 4
4 · LIGAND PHARMACEUTICALS INC · Filed Jun 9, 2026
Research Summary
AI-generated summary of this filing
Ligand (LGND) Director John W. Kozarich Receives RSU Award
What Happened
John W. Kozarich, a director of Ligand Pharmaceuticals, was granted a total of 3,774 restricted stock units (RSUs) on June 5, 2026. The filing reports two grant entries: 836 RSUs (acquired) and 2,938 RSUs recorded as a derivative award; both show $0.00 per share (no cash exchanged). These RSUs are contingent rights to receive shares upon vesting.
Key Details
- Transaction date: 2026-06-05; Filing date: 2026-06-09 (filed on time).
- Grants: 836 RSUs (A) and 2,938 RSUs (A, derivative) — total 3,774 RSUs; reported price $0.00.
- Vesting: Grants fully vest on the earlier of (A) the next annual meeting of stockholders after the grant date or (B) the first anniversary of the grant (per footnotes).
- Shares owned after transaction: Not specified in the filing.
- Footnotes: F1/F2 confirm these are RSUs (each convertible to one share upon vesting) and were approved by the Board at the annual meeting.
Context
This is a routine equity award to a director as part of compensation and does not represent an open-market purchase or sale. RSUs are contingent (derivative) rights and will convert into actual shares only if and when they vest; such awards do not by themselves signal an immediate buying or selling intent.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-05+836→ 42,622 total - Award
Non-Qualified Stock Option (right to buy)
[F2]2026-06-05+2,938→ 2,938 totalExercise: $237.00Exp: 2036-06-05→ Common Stock (2,938 underlying)
Footnotes (2)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
- [F2]Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.